Navigation Links
AbbVie Reports Third-Quarter 2013 Financial Results
Date:10/25/2013

5)

n/a

n/a

(69.5)

(69.5)Duodopa

--

129

129

n/a

16.6

19.4

16.6

19.4Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations.
n/a = not applicable  AbbVie Inc.
Consolidated Statements of Earnings
Quarter and Nine Months Ended September 30, 2013 and 2012
(Unaudited) (In millions, except per share data)Third Quarter Ended September 30Nine Months Ended
September 302013201220132012Net sales

$4,658$4,508$13,679$13,174Cost of products sold

1,0921,0143,2993,243Selling, general and administrative

1,2611,0853,9043,578Research and development

7148132,0572,097Acquired in-process research and development

220--290260Total operating cost and expenses

3,2872,9129,5509,178Operating earnings

1,3711,5964,1293,996Interest (income) expense, net

69(1)210(4)Net foreign exchange (gain) loss

1164027Other (income) expense, net

5(13)(14)(39)Earnings before income tax

1,2861,6043,8934,012Income tax expense

32219893277Net earnings

$964$1,585$3,000$3,735Diluted earnings per share

$0.60$1.01$1.86$2.37Average diluted shares outstanding1,6051,5771,6021,577Note: On Jan. 1, 2013, Abbott Laboratories distributed 1,577 million shares of AbbVie common stock to Abbott's shareholders in connection with the separation of AbbVie from Abbott. The computation of diluted earnings per share for the quarter and nine months ended Sept. 30, 2012 was calculated using the shares distributed on Jan. 1, 2013. AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
Quarter Ended September 30, 2013
(Unaudited) (In millions, except per share data)1. Specified items impacted results as follows:3Q13Earnings

DilutedPre-tax

After-tax

EPSAs
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. AbbVie Named a Science Top Employer
2. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
3. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
4. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
6. AbbVie Declares Quarterly Dividend
7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
8. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
9. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
10. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
11. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- This is a professional ... Heparin sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) ... of Heparin sodium (CAS 9041-08-1) & calcium (CAS ... The report then explores global and China,s top ... (CAS 37270-89-6) listing their product specification, capacity, production ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
(Date:7/30/2014)... California , July 30, 2014 ... technology and CUDA programming expertise to big data, ... markets  eInfochips, a leading engineering R&D ... clients to develop NVIDIA GPU-powered solutions for ... high-performance computing (HPC), industrial , ...
Breaking Medicine Technology:Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2
... Reportlinker.com announces that a new market research ... Pharmaceuticals: Global Industry Guide ... Pharmaceuticals: Global Industry Guide is ... analysis covering the Pharmaceuticals industry. It includes ...
... 2012 Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE ... three lead drugs (Zertane™ completed two phase ... licensing distribution of these drugs and engaged in further ... interim review of the first 50% of patients enrolled ...
Cached Medicine Technology:Pharmaceuticals: Global Industry Guide 2Pharmaceuticals: Global Industry Guide 3Pharmaceuticals: Global Industry Guide 4Pharmaceuticals: Global Industry Guide 5Pharmaceuticals: Global Industry Guide 6Pharmaceuticals: Global Industry Guide 7Pharmaceuticals: Global Industry Guide 8Pharmaceuticals: Global Industry Guide 9Pharmaceuticals: Global Industry Guide 10Pharmaceuticals: Global Industry Guide 11Pharmaceuticals: Global Industry Guide 12Pharmaceuticals: Global Industry Guide 13Pharmaceuticals: Global Industry Guide 14Pharmaceuticals: Global Industry Guide 15Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 2Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 3Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 4
(Date:7/30/2014)... Rancho Cucamonga, CA (PRWEB) July 30, 2014 ... career learning how to make millions. However, like most people, ... all. Determined to find a better way, Paul carefully ... lasting wealth and those who do not. Based on the ... learned to not only improve his life and health, but ...
(Date:7/30/2014)... sub-Saharan Africa is being revitalized and expanded through ... broadening curricula, upgrading Internet access and providing cutting-edge ... the first substantial publication by participants of the ... than 225 authors detailed progress being made at ... supplement being published today by the journal ...
(Date:7/30/2014)... July 30, 2014 Good Neighbor ... in an upcoming episode of Innovations with Ed ... Channel. Dates and show times TBA. , In ... Neighbor Community Services’ vision to redefine the traditional ... and dynamic services. Through passion, innovation, determination, excellence, ...
(Date:7/30/2014)... -- It can happen in an instant: A small child ... and gets critically injured when the furniture tips over. ... around their homes and imagine what could tip over, fall ... than it becoming a reality," Dr. Alex Rosenau, president of ... news release. Between 2009 and 2011, roughly 43,000 people ...
(Date:7/30/2014)... cancer as well as evolutionary changes in a living ... randomly throughout the genome. , However, recent studies have ... multiple mutations that arise simultaneously and in close proximity ... frequently found in regions where chromosomal rearrangements take place. ... Reports , may one day lead to new cancer ...
Breaking Medicine News(10 mins):Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2
... macular degeneration, also called juvenile macular degeneration, is an ... This condition results from a defect in the ABCR ... that removes all-trans-retinaldehyde, a vision byproduct, from retinal rods ... epithelium (RPE), a layer of cells near the retina. ...
... inflammatory condition of the bladder wall. It typically affects ... men. Investigators are testing the bacteria Bacillus Calmette-Guerin(BCG), which ... treating interstitial cystitis, by inserting six installations into the ... study of BCG// also showed that 60 percent of ...
... a screening of the colon do not go through ... procedure that is currently available involves inserting a flexible ... requires anaesthesia and there's a remote chance that the ... patients now have an easier option with the discovery ...
... worldwide and its incidence is high in the Asian and ... foodstuffs. The cancer is also becoming prevalent in the United ... gene activity in liver tumors using the new 'gene chip' ... They found that there is a difference between// those tumors ...
... has shown that infants born during night time have ... to those born during day time. Previous studies have ... weekends and holidays have an increased risk of death ... experienced staff for better obstetric and neonatal care during ...
... Vitamin C has been believed, over the years, to be a ... proved to be true by researchers who have studied changes in ... their study of 12 healthy subjects who took one gram of ... immune system response in all of them during the period. Their ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: